UK Public Sector Contracts & Tenders

Radiation Protection Advisory Service NHS Blood & Transplant (NHSBT) intends to undertake a procurement tender exercise for the provision of a Radiation Protection Advisory (RPA) and Radiological Waste Advisory (RWA) service. NHSBT (England) now wishes to commence a formal procurement process and is seeking to engage with suppliers for the provision of RPA/RWA services. The current contract ends in 31/03/2027. NHSBT would like to improve our knowledge of all current RPA/RWA services available in the marketplace. This will aid identification of opportunities and gauge market interest in this field. We require the services to cover the following: - • RPA/RWA services in compliance with Ionising Radiation Regulation 2017 (IRR17). • RPA/RWA services in compliance with Environmental Permitting Regulations 2016 (EPR16). • RPA/RWA services in compliance with NaCTSO Security Requirements Document (SRD) 2024. • Industrial irradiation continuing consent advice to the Health and Safety Executive (HSE). • Technical review of dose mapping reports. • Calibration of radiation monitors. • Annual site visit to each of the centres to audit compliance to regulatory standards. • Advice in the event of an emergency (cover provided 24/7 due to the operational requirements of NHSBT). It is NHSBT's intention to hold pre-procurement supplier engagement meetings the week of May 5rth 2026 to June 5th 2026. the meetings will be held remotely, the dates are to be confirmed. To enable NHSBT to finalise arrangements (e.g. send meeting details and agree time slots) for the meeting’s, interested organisations are required to send an expression of interest via email to Sahithi Bandi - sahithi.bandi@nhsbt.nhs.uk no later than 17:0 hrs (GMT) on 29/05/2026. This should include a list of your potential attendees and a brief overview (or a website link) of the Goods / Services which might be offered. No business whatsoever is guaranteed under any resulting framework agreement or contract, and there is no guarantee that any framework agreement or contract will be put in place in relation to this notice. No compensation etc. will be paid if a tender or resulting framework agreement is withdrawn for any reason. Bidders should take part in this process only on the basis that they fully understand and accept this position. It should be noted that this procurement exercise may allow other Health authorities to use any agreements awarded.

NHS Blood and Transplant (NHSBT) is undertaking preliminary market engagement to inform its procurement and commercial strategy for future logistics services, including courier transport and associated logistics requirements supporting NHSBT’s supply chain. This engagement forms part of NHSBT’s wider market engagement and commercial planning for future logistics services and is intended to further inform the scope, delivery model and procurement approach for any future opportunity. This engagement is intended to help inform the shape of the opportunity and should not be taken to indicate that NHSBT has selected any particular solution, structure or supplier approach. NHSBT currently supports inhouse fleet with a multi-supplier model for courier logistics services, with separate contracts and arrangements supporting the collection, transport and delivery of blood and blood components, plasma, organs, tissues, samples, clinical materials and associated support functions. This varied approach has opportunities to improve: • co-ordination and integration across courier operations; • resilience in some services or locations; • service levels; • reporting and performance monitoring; NHSBT is considering future delivery model options in order to support: • improved operational efficiency and resilience through greater co-ordination across NHSBT fleet and third-party logistics services; • an enhanced solution for dynamic planning across all operations; • consistent service standards across courier operations and locations; • simplified governance and accountability; • enhanced data visibility and performance insight; and • improved value for money through a more co-ordinated and effective service approach. The purpose of this preliminary market engagement is to: • provide background and context to the proposed procurement; • test the proposed scope and potential delivery model options; • better understand market capability, capacity and key risks; • understand potential mobilisation timetable from potential suppliers to ensure the estimated procurement timetable is realistic and to minimise transition risk; • obtain supplier insight on operating models, service integration, mobilisation, resilience, transport planning solutions including dynamic planning, data visibility, governance, commercial arrangements and performance management; and • inform NHSBT’s future commercial strategy and procurement approach. Areas which may be in scope for discussion as part of this engagement include: • scheduled and ad hoc transport; • courier and urgent response services; • specialist clinical logistics; • national and/or regional courier logistics; • control tower, visibility and booking systems; • contingency for “shock” events; • mobilisation, continuity and service resilience; and • 3rd party storage and warehousing to support inhouse provision.

Invitation to offer for the supply of Pharmacy Homecare Medicine Services – Low and Mid Tech with optional healthcare professional led services to NHS patients within the South West region. Participating Trusts include: • Dorset County Hospital NHS Foundation Trust • Gloucestershire Hospitals NHS Foundation Trust • Great Western Hospitals NHS Foundation Trust • Gloucestershire Health & Care NHS Foundation Trust • North Bristol NHS Trust • Royal Cornwall Hospitals NHS Trust • Royal Devon University Healthcare NHS Foundation Trust • Royal United Hospitals Bath NHS Foundation Trust • Salisbury NHS Foundation Trust • Somerset NHS Foundation Trust • Torbay & South Devon NHS Foundation Trust • University Hospitals Plymouth NHS Trust • University Hospitals Bristol & Weston NHS Foundation Trust • University Hospitals Dorset NHS Foundation Trust • Dorset Healthcare University NHS Foundation Trust Any other NHS organisation in the South West of England region may join this Framework Agreement at any time during the framework period.

The requirements for the provision of a comprehensive, compliant, and reliable personal dosimetry and environmental radiation dose monitoring service. The service shall support effective radiation protection, regulatory compliance, and occupational safety for staff, patients, the public, and the environment. The Contractor shall deliver a complete personal radiation monitoring service for both classified and non‑classified radiation workers. This shall include a range of dosimetry solutions such as whole‑body personal dosimeters, extremity dosimeters (ring or wrist), eye lens dosimeters where applicable, and area‑ or task‑specific personal dosimeters as required. The service shall include the provision and management of suitable dosimeters in adequate quantities. Each dosimeter shall have a unique identification and be correctly assigned to individual workers. The Contractor shall manage regular exchange cycles, such as monthly or quarterly as agreed, and provide replacement dosimeters for those that are lost or damaged. Clear instructions shall be issued to users on the correct use and care of dosimeters. Dose measurement and analysis shall be carried out through accredited laboratory processing and evaluation. The service shall measure external radiation doses and calculate personal dose equivalents. Any abnormal, high, or unexpected dose readings shall be investigated and reported, with dose trend analysis made available upon request. Reporting shall include the provision of individual dose reports within agreed turnaround times, cumulative dose records for each worker, and summary reports for the employer. The Contractor shall provide immediate notification of any dose exceedances or levels requiring investigation. Secure electronic access to dose data and reports shall be available. The Contractor shall ensure secure storage and maintenance of lifetime dose records. Dose records shall be transferable upon request or at contract termination, with full compliance with data protection and confidentiality requirements. In addition, the Contractor shall provide environmental radiation dose monitoring services to assess radiation levels within and around facilities. This shall include the supply of calibrated environmental dosimeters or detectors for both indoor and outdoor use, along with advice on installation and siting in accordance with best practice. Environmental monitoring activities shall consist of routine dose measurements at agreed locations, periodic collection and replacement of dosimeters, and evaluation of ambient radiation levels and trends. Where required, additional monitoring shall be undertaken following incidents or operational changes. The Contractor shall produce regular environmental monitoring reports, including comparisons against background radiation and historical data. Results shall be interpreted clearly, with abnormal readings identified. Immediate notification shall be provided if predefined action or investigation levels are exceeded. The Contractor shall hold appropriate accreditation for dosimetry and radiation monitoring services and comply with all applicable radiation protection legislation and guidance. A documented quality management system shall be in place, and all equipment calibration shall be traceable to recognised national or international standards. Service levels shall include defined turnaround times for dosimeter processing and report delivery, named technical and customer support contacts, and access to helpdesk or advisory support for radiation protection queries. Clear procedures shall be established for incident escalation and response. All personal and environmental data shall be handled in compliance with applicable data protection legislation. Data shall be stored securely, with access restricted to authorised users only. The Contractor shall provide user guidance on dosimeter responsibilities and correct use, support radiation protection audits and inspections, and offer technical advice relating to dose results and regulatory compliance. Unless otherwise agreed, the scope of service shall exclude radiation protection supervision or advisory services, risk assessments or controlled area designation, the supply of fixed radiation monitoring systems beyond passive environmental dosimeters, and remedial actions arising from dose exceedance investigations. The service shall be subject to periodic review, including performance reporting against agreed key performance indicators. The Contractor shall demonstrate a commitment to continuous improvement in service delivery and reporting.

The Trust is seeking to award a contract for the provision of a Mental Health Crisis House in Somerset. The successful provider will proactively manage and deliver all care and support required, within a residential setting based in Taunton or Yeovil.

Water risk assessments and water testing, including sentinel outlet and shower sampling. The value stated represents the total SASC requirement; however, only the SWAST element of this value is guaranteed.

Universities Hospital Dorset (UHD) is seeking a high quality, reliable and resilient bus shuttle solution to support inter-site travel for staff and members of the public. The contract is initially being offered on a three (3) year basis with an optional two (2) years further.

NHS Bath and North East Somerset, Swindon and Wiltshire (BSW) Integrated Care Board, NHS Somerset Integrated Care Board and NHS Dorset Integrated Care Board are currently working together in a formal "clustering" arrangement to prepare for their merger into a single, new organisation (name to be confirmed), effective from 1st April 2027. The commissioners are seeking to secure suitably qualified provider(s) who have the capability and capacity to deliver sight testing to children and young people in special educational settings (SES) across the BSW, Somerset and Dorset footprints in line with the specified requirements. The service will be procured as one lot. The service will provide routine appointments, triage and treatment to all children and young people with SEND needs in residential and day SES within BSW, Somerset and Dorset (including Bournemouth and Poole) with onward referral where appropriate. Key Service Objectives: • Providing annual sight tests in the school setting (unless a more frequent interval is clinically indicated). • Close collaboration with school staff, parents, and carers • Provide guidance and support based on individual specific needs and their medical history. • Obtain written consent from pupils/parents/carers/guardians. • Enable attendance from parents/carers/guardians to the sight test and selection of frames. • Offer a range of suitable frames or NHS optical voucher for high street use. • Provide an eye health outcome and vision report. • Appropriate onward referral. The contract will be for an initial 3 year term with an optional extension of any period up to 2 years. This is a new service; therefore TUPE does not apply. The new service will commence on the 1st April 2027. This procurement is being carried out by NHS South, Central & West (SCW) on behalf of the commissioners. SCW is currently subject to restructuring, and the management of this procurement may therefore move to a successor at some point during the procurement process.  Bidders will be informed of any such change, and any administrative changes because of it.

Great Western NHS Foundation Trust (the “Trust) opened its acute Private Finance Initiative (PFI) facility in 2002. The six-storey building provides 78,101 square meters of internal space and supports 650 beds. The hospital includes a full range of acute services, including an Accident and Emergency department, Acute Assessment Unit, Intensive Care / High Dependency Unit, Maternity and Intermediate Care Centre. The site also incorporates a health and social care education centre (the “Academy”), alongside a wide range of wards and clinics, serving a population of around 300,000 people. The PFI contract is due to expire in October 2029 and covers approximately 90% of the Trust’s estate on the Swindon site. The majority of the facilities management (FM) services for the PFI estate (excluding car parking, linen and transport which are a directly delivered service by the Trust) are currently provided under the PFI contract. FM services to the retained estate (non-PFI) estate are outsourced separately. However, many of the same service providers deliver FM services across both the PFI and non-PFI estate. The Trust is currently considering a range of future FM service delivery models across the Swindon site and is seeking to engage with the market to understand the industry perspective. This engagement will help inform the Trust’s approach to its future service delivery strategy. The FM services currently included within the assessment are: 1. Estates maintenance service, including planned, reactive, small work’s, project works etc. 2. Grounds maintenance service 3. Energy and utilities management service 4. Helpdesk service and CAFM system 5. Cleaning service 6. Catering (patient and retail) service 7. Portering service 8. Security service 9. Pest control service 10. Waste management and disposal service 11. Switchboard service 12. Tenancy and residential property management service 13. Linen and laundry 14. Car parking management The Trust is seeking to understand market capability, capacity, and innovative approaches regarding the delivery of the full suite of FM services across its estate, as well as understanding the markets appetite for differing FM service contract bundling arrangements. Any future contract(s) may be split into lots e.g. a number of separate contractual arrangements or delivered as in interacted combined FM service solution. The Contracting Authority wishes to involve the market in discussing the following general points: • Current market and market interest in this project • Relevant experience • Feedback on the service structure / service lotting structure • Key risks and commercial terms of interest • Contract term and investment • Innovations in the market place • Continuous improvement Suppliers who wish to participate in the preliminary market engagement are to express their interest by the closing date and time on the following portal https://atamis-1928.my.site.com/s/Welcome Supplier can register/login to atamis and find under - Atamis Reference: C451357 Engagement process description: A preliminary market engagement session will be conducted virtually via Microsoft Teams on 16th June 2026 10:00 hours to 12:00 hours. Joining details will be issued by the Trust to your confirmed point of contact prior to the event. To ensure consistency, this event will be recorded and shared with any Suppliers unable to attend, but still wishing to engage. Suppliers are asked to confirm the names, email and titles of the attendees to the preliminary market engagement virtual session prior to the session, via the portal. A Market Engagement Questionnaire (MEQ) will be available via the portal under Supplier Documents Folder at the point of expressing interest via the above link to allow sufficient time for suppliers to complete and respond. Market Engagement Closing Date and Time: Suppliers are asked to return the completed MEQ via the portal by 14:00 hours on Wednesday 1st July 2026. Suppliers are requested to direct all queries via the Portal rather than make direct contact with the Trust.

Call for Expression of Interest only, (NON COMPETITIVE) for the provision of talking therapies services to the those aged 16 and over who are registered with a GP within Cornwall and the Isles of Scilly.<br/><br/>The service commencement date is Thursday 1st April 2027. <br/><br/>Please note the deadline for expressions of interest is 12:00PM (MID-DAY) on FRIDAY 26 JUNE 2026.<br/><br/>Any related procurements will be in accordance with the Provider Selection Regime(PSR) Regulations and Guidance. The awarding of this contract will be subject to the Health CareServices (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023, will not apply to this award.

The Clinical Biotechnology Centre at NHS Blood and Transplant is an MHRA-licensed facility for the manufacture of investigational medicinal products, including advanced therapy medicinal products (ATMPs) and other biotechnology products such as plasmid DNA, viral vectors, and therapeutic proteins. The organisation intends to initiate a procurement process for the supply of advanced, high-performance, and cost-effective endonucleases to support the removal of nucleic acids from ATMPs, particularly gene therapy vectors, including adeno-associated viral (AAV) vectors and lentiviral vectors. The endonuclease must exhibit non-specific nuclease activity against a broad range of nucleic acid substrates, including DNA, RNA, plasmid DNA, synthetically produced DNA, enzymatically produced DNA, and other nucleic acid modalities used in viral vector manufacturing. The enzyme should retain activity under physiological pH and salt conditions, while also maintaining high enzymatic performance across a broad pH and salt concentration range. Demonstrated suitability for use in viral vector manufacturing processes employing HEK293 suspension cells cultured in stirred-tank bioreactors will be considered an advantage. Suppliers should also demonstrate that residual endonuclease can be efficiently removed from the viral vector product using a defined set of purification methods commonly applied in bioprocessing. A key requirement is the availability of GMP-qualified and validated analytical assays for the quantification of residual endonuclease at different stages of the manufacturing and purification process. The supplier must provide such assays either directly or through authorised analytical service providers. The supplier should be able to provide endonuclease in multiple quality grades, including R&D grade, GMP-compatible grade, and GMP-qualified grade. It is also essential that these materials are available in quantities suitable for small, medium and large-scale production. Suppliers must provide comprehensive technical and scientific documentation to support the quality attributes and performance characteristics of the endonuclease. Enzymatic activity should be demonstrated using appropriate standards or reference materials relevant to viral vector manufacturing. Overall, the endonuclease must be highly efficient, scalable, and cost-effective, and suitable for the manufacture of clinical-grade viral vectors. Appropriate analytical methods must also be available to support testing of product quality and residual endonuclease levels in drug products intended for human clinical use, in accordance with applicable national and international regulatory requirements.

The Specification sets out the requirements for the Personal Dosimetry Service to be delivered under contract to the Authority. The service encompasses the supply, distribution, collection, processing, and reporting of personal dosimeters worn by classified radiation workers across the Authority’s site.<br/>The Authority is required under the Ionising Radiations Regulations 2017 (IRR17) requires GHNHSFT as a radiation employer to risk assess all work with ionising radiation and potential radiation exposure to staff during their work and identify whether staff require personal dose monitoring or SHOULD be designated as classified persons. Personal dose monitoring is used to demonstrate that doses are as low as Reasonably practicable (ALARP) & compliant with regards to the Dose limits (Schedule 3 of the Ionising Radiations Regulations 2017. It is an offense under IRR17 to exceed the dose limits. The Supplier must demonstrate full compliance with these obligations and with all relevant legislation, standards and guidance as specified herein.<br/>Employers are responsible for dose assessment & recording (reg 22). Prompt investigation of overexposure where a dose to a worker exceeds dose limits is required (Reg 26), review of staff dose monitoring records enables investigations to be carried out when lower local dose investigation levels are exceeded to ensure learning and other actions are taken before the individual exceeds the statutory dose limits.<br/>For all workers designated as Classified Persons (Reg 36) the radiation employer (GHNHSFT) MUST employ an Approved Dosimetry Service (Reg 22) which has HSE approval for dose assessment, co-ordination, record keeping and sharing of dose information with the HSE’s central index of Dose information (CIDI).<br/>The current contract for the provision of HSE Approved Dosimetry Services is held with the Radiation physics and Protection Services (RRPPS) ADS at University Hospitals Birmingham. Tender reference RFT43347 which was commenced on 01/08/2021, for an initial period of 3 years with and extension clause of up to 2 years and therefore the contract is due for renewal & retender in August 2026.<br/>The purpose of this scope is to define the requirements for the provision of a comprehensive, compliant, and reliable personal dosimetry and environmental radiation dose monitoring service to support radiation protection, regulatory compliance, and occupational safety for staff, patients, the public, and the environment.

The Royal United Hospitals NHS Foundation Trust is exploring options to expand its Radiopharmacy Services to improve access to diagnostics, innovative treatment and research in Southwest England. Uniquely positioned on the M4/M5 corridor, the Trust has a state-of-the-art Pharmacy build intended to provide a comprehensive range of services including: 1. Cytotoxics (191 sq ft): mainly production of systemic anticancer therapy (SACT) and clinical trials for Onc/Haem 2. Monoclonal antibodies (180 sq ft): products for Biologics unit and chemo unit 3. Radiopharmacy unit (279sq ft): supply for Nuclear medicine diagnostics & treatment 4. Vacant clean room space originally intended for Gene Therapy (108 sq ft) As part of this appraisal, the Trust is evaluating a range of potential delivery and funding models, including the possibility of a Joint Venture or other form of partnership with a private sector organisation. The purpose of this soft market testing exercise is to gain insight into: • The level of interest from suppliers and investors in collaborating with the Trust • The range of commercial, technical and operational models available within the market • Key risks, dependencies and potential mitigation approaches • Options that best ensure service continuity • Indicative timelines and delivery pathways This exercise is being undertaken for information gathering purposes only and does not constitute a call for competition or form part of any formal procurement process. The responses received will be used to inform the Trust’s approach and any potential future procurement activity. Please note, Royal United Hospitals Bath NHS Foundation Trust reserves the right not to proceed with the procurement once this Pre-Engagement stage has been finalised.

BWPC (Bristol & Weston NHS Purchasing Consortium), plan to utilise the NHS Workforce Alliance RM6276 - Insourced Services - NHS Workforce Alliance to support the Provision of Healthcare and thereby conduct a mini-competition under this Framework.  Only suppliers awarded under this Framework will be eligible to submit a bid.  This procurement will be governed by the NHS Provider Selection Regime.

NHS Dorset ICB, along with partners Health Innovation Wessex and Bournemouth University, would like to invite potential partners, providers and innovators to a soft market engagement conversation, with an opportunity to co-design personalised pathways to healthy weight for underserved populations in Dorset. This work builds on NHS Dorset's commitment to reducing childhood obesity by 2040 (Outcome 2 - NHS Dorset https://nhsdorset.nhs.uk/voice/jointforwardplan/outcome-2/) and improving access, experience and outcomes for people living with unhealthy weight and obesity, most recently supporting access to medicated and non-medicated pathways for adults in line with the NICE Technology Appraisal NG246 (Weight management - NHS Dorset https://nhsdorset.nhs.uk/health/medicines/weight/) Our aim is to further transform weight management services in Dorset, by developing and testing an inclusive, community-based model that addresses the persistent inequalities in access, experience and outcomes for underserved populations and tackles the underlying causes of obesity. Our objectives are to: • Co-produce and test innovative models of care that integrate pharmacological, digital, and behavioural approaches for healthy weight. • Reduce health inequalities by improving access to care for underserved populations, including for people with experience of the care system; people with learning disabilities; people with special educational needs and disabilities; and mental health service users. • Build capacity within our workforce and communities to support sustained healthy lifestyles and self-management. • Embed a whole-system, data-driven approach to tackling obesity as a major driver of long-term conditions • Enable real-world evaluation and learning that can inform national policy and future service commissioning. The Dorset Model proposes to: • Recruit participants to the programme by pro-actively case finding through our Dorset Insight and Intelligence Service (DiiS) and through trusted people and places, making every contact count. • Offer a personalised multi-disciplinary team conversation, which recognises the lived experience of participants, and provides a tailored care plan, with support from a lead professional or coach. • Deliver personalised pathways to health weight through evidence-informed and co-produced interventions. This might include; in-person groups, remote groups, digital technologies (platforms/wearables), pharmacological and in-service pathways, for individuals, families and carers, and communities. • Integrate new care pathways and interventions with existing system weight management services, to support both sustainable healthy weight on discharge for individuals and better access to standard care for family, carer, and community members. • Build knowledge, skills and confidence in our health, social care and VCSE workforce, including paid and unpaid roles. NHS Dorset anticipates procuring suitably qualified provider(s) to: (1) A Prime Provider to act as System Integrator for the Programme, who may choose to deliver some or all elements of the new service(s). (2) Organisation(s) to deliver new services, including digital, behavioural, lifestyle and health improvement, with individuals, families, carers and communities. (3) Organisation(s) to deliver workforce development.

Supply of Hips and Knees (Primary and Revision)

Microsoft Enterprise Software Agreement (Licensing)

Re-procurement of cleaning service for the Trust's community sites.

Provision of PCs, Laptops, Servers and Storage

The NHS England South West are planning for the re-commissioning of School Aged Immunisation Services in Dorset. This notice is placed as a Prior Information Notice in order to facilitate a virtual market briefing event. NHS England South West invites suitably qualified and experienced providers to express their interest in attending a virtual market briefing event which is currently expected to be held on Tuesday 2nd June at 10:30am. This is intended to build on the market engagement that took place during November and December 2025. The event will include the commissioning vision, an overview of the services, the procurement process, and an opportunity for Q&A. If you are interested in attending the virtual market briefing event, please express an interest via Atamis. Please send a message via the portal with the names of the personnel who are likely to attend the market briefing event. Further details in relation to registering on Atamis can be found at the end of this notice.